MAP2K1 and melanoma: Trametinib (MekinistTM Novartis, Mission Viejo, California, USA), a MEK 1/2 inhibitor, has shown therapeutic promise as either a monotherapy for BRAF-mutant melanoma or in combination with dabrafenib.